kcc-3 Antibody

What is KCC-3 and why is it important in research?

KCC-3 is a potassium-chloride cotransporter protein that plays significant roles in ionic and osmotic homeostasis across various cell types. Unlike other KCC isoforms (KCC1 and KCC4) that respond primarily to osmolality changes, KCC-3 has been linked to cellular proliferation and growth regulation, making it a target of interest in developmental and cancer research. KCC-3 was initially cloned from vascular endothelial cells but has since been found to have wide, though not universal, distribution in tissues. Studies have demonstrated that KCC-3 activity is regulated by tyrosine phosphorylation and is sensitive to inhibitors such as [(dihydroindenyl)oxy] alkanoic acid (DIOA) and N-ethylmaleimide . Importantly, while KCC1 and KCC4 are involved in volume regulation, KCC-3 appears to have distinct physiological roles, including potential involvement in cell cycle progression.

How do I select the appropriate KCC-3 antibody for my experimental needs?

When selecting a KCC-3 antibody, consider several critical factors:

• Isoform specificity: Determine which KCC-3 isoform (KCC3a, KCC3b, or KCC3c) is relevant to your research. Studies have identified multiple isoforms with molecular weights of approximately 150 kDa (KCC3a), 122 kDa (KCC3b), and possibly 105 kDa (KCC3c) .

• Target epitope: Antibodies targeting different epitopes show varying detection profiles. For example, antibodies against the large extracellular loop 3 (ECL3) may detect different isoforms compared to those against the C-terminal domain (CTD) .

• Application compatibility: Verify the antibody's validated applications (Western blotting, immunofluorescence, immunohistochemistry) align with your experimental needs.

• Species reactivity: Ensure compatibility with your model system. The literature shows successful use of rabbit anti-human KCC3 antibodies in human tissue samples and cell lines, while other studies utilize species-specific antibodies .

• Validation status: Prioritize antibodies with published validation data. For instance, reference mentions a "rabbit polyclonal KCC3 antibody (1:200, antibody validated in Ref. 11)."

What are the recommended dilutions for KCC-3 antibody in different applications?

Based on published research protocols, the following starting dilutions are recommended:

For double staining procedures, such as co-localization with parvalbumin, a sequential staining protocol may be necessary. One validated approach involves incubating with KCC-3 antibody first (1:200, room temperature for 1.5h then overnight at 4°C), followed by secondary antibody incubation (FITC antibody at 1:200) for 2 hours at room temperature, blocking with unconjugated Fab antibody (1:20) for 1 hour, and then proceeding with the second primary antibody .

How can I distinguish between different KCC-3 isoforms in my samples?

Distinguishing between KCC-3 isoforms requires careful selection of detection methods and antibodies:

• Western blotting approach: Use antibodies targeting different epitopes to identify distinct molecular weight bands. Research has shown that rabbit anti-human KCC3-ECL3 antibodies can detect three bands at approximately 150 kDa (KCC3a), 122 kDa (KCC3b), and 105 kDa (possibly KCC3c). Meanwhile, antibodies targeting the C-terminal domain (anti-hmKCC3-CTD) may detect only the 122 kDa and 112 kDa bands .

• RT-PCR verification: Complement protein detection with isoform-specific primers for RT-PCR analysis. This approach can confirm the presence of specific isoform transcripts (KCC3a, KCC3b) at the mRNA level before proceeding with protein analysis .

• Control samples: Include positive controls with known isoform expression. For example, human cervical cancer SiHa cells have been used as positive controls for KCC-3 expression .

• Quantitative comparison: Perform semi-quantitative RT-PCR with β-actin as an internal standard to assess relative expression levels of different isoforms under various experimental conditions .

• Tissue-specific patterns: Be aware that isoform distribution varies across tissues. For instance, studies have detected KCC3a and KCC3b in human lens epithelial B3 cells but failed to detect any KCC3 isoforms in cataractous lens tissue samples using the same antibodies .

What fixation and antigen retrieval methods are optimal for KCC-3 immunodetection in tissue sections?

Successful immunodetection of KCC-3 in tissue sections requires specific fixation and antigen retrieval protocols:

• Fixation protocol: For optimal preservation of KCC-3 epitopes in tissues such as dorsal root ganglia (DRG), a recommended protocol involves:

  • Immediate post-mortem dissection

  • Fixation in 10% formalin at room temperature overnight

  • Paraffin embedding and sectioning at 10-μm thickness

• Deparaffinization: Dissolve paraffin using Citrisolv (Thermo Fisher Scientific) followed by tissue rehydration through an ethanol gradient:

  • 5-minute washes in 100% ethanol

  • 5-minute washes in 95% ethanol

  • 5-minute washes in 70% ethanol

  • 10-minute wash in 1× PBS

• Antigen retrieval: Critical for unmasking epitopes after fixation, use Citra Plus (BioGenex) or a similar citrate-based retrieval solution. This step significantly improves antibody binding and signal intensity .

• Blocking conditions: For optimal signal-to-noise ratio, block sections with a buffer containing:

  • 5% bovine serum albumin

  • 1% goat serum (or serum matching secondary antibody host)

  • 0.5% Triton X-100

  • Block for 2 hours at room temperature before antibody application

How can I confirm the specificity of my KCC-3 antibody signal?

• Genetic controls: Utilize KCC-3 knockout or knockdown models as negative controls. The literature describes KCC3-flox and KCC3-rescue mouse models that can serve as valuable specificity controls .

• Peptide competition assay: Pre-incubate your antibody with the immunizing peptide before application to your samples. Specific signals should be significantly reduced or eliminated.

• Multiple antibody approach: Use antibodies targeting different KCC-3 epitopes and compare detection patterns. Consistent results across antibodies targeting different regions (like ECL3 versus CTD) provide stronger evidence for specificity .

• Correlation with mRNA expression: Perform RT-PCR analysis to correlate protein detection with mRNA expression. Cell lines showing positive RT-PCR results for KCC3 should also show antibody reactivity in Western blots and immunocytochemistry .

• Cellular localization patterns: Evaluate whether the observed localization pattern matches known KCC-3 distribution. Fluorescence microscopy has demonstrated both cytoplasmic and membrane labeling patterns for KCC-3 in validated cell lines .

How can I design experiments to study KCC-3 phosphorylation status and its functional significance?

Studying KCC-3 phosphorylation requires sophisticated experimental approaches:

• Phospho-specific antibodies: Select antibodies specifically targeting phosphorylated residues of KCC-3. Research has established that KCC-3 activity is regulated by tyrosine phosphorylation , so phospho-tyrosine-specific KCC-3 antibodies are valuable tools.

• Phosphatase treatment controls: Include samples treated with alkaline phosphatase prior to immunoblotting to confirm phosphorylation-dependent signals.

• Kinase and phosphatase modulators: Design experiments incorporating:

  • Tyrosine kinase inhibitors (e.g., genistein)

  • Tyrosine phosphatase inhibitors (e.g., sodium orthovanadate)

  • Serine/threonine phosphatase inhibitors (e.g., okadaic acid)

  • Monitor changes in KCC-3 phosphorylation status and correlate with functional activity

• Functional correlation: Combine phosphorylation detection with functional assays, such as 86Rb+ flux measurements to assess KCC-3 activity. Research has demonstrated that KCC-3 activity is sensitive to treatments affecting tyrosine phosphorylation status .

• Site-directed mutagenesis: Generate KCC-3 constructs with mutations at putative phosphorylation sites to determine their functional relevance through transfection studies in appropriate cell models like NIH/3T3 fibroblasts .

What methodological approaches are recommended for studying KCC-3 regulation by growth factors and cytokines?

KCC-3 regulation by external factors requires specific experimental designs:

• Serum starvation conditioning: Prior to growth factor/cytokine treatment, culture cells in serum-free medium for 24 hours to establish baseline KCC-3 expression and activity levels .

• Dose-response analysis: Treat cells with increasing concentrations of factors known to regulate KCC-3, such as:

  • Insulin-like growth factor-1 (IGF-1): Demonstrated to stimulate KCC3 activity dose-dependently

  • Tumor necrosis factor-α (TNF-α): Shown to inhibit KCC3 activity dose-dependently

• Time-course experiments: Monitor changes in KCC-3 expression and activity at multiple time points following treatment to capture both immediate and delayed regulatory effects.

• Multi-level analysis: Assess regulation at different levels:

  • mRNA expression (RT-PCR)

  • Protein expression (Western blotting)

  • Subcellular localization (immunofluorescence)

  • Functional activity (86Rb+ flux assays)

• Pathway inhibitor studies: Use specific signaling pathway inhibitors to delineate the mechanism of KCC-3 regulation. For example, inhibitors of the PI3K/Akt pathway could be used to test whether IGF-1's effects on KCC-3 are mediated through this signaling cascade.

How do I design co-localization studies for KCC-3 with other neuronal markers?

Co-localization studies require careful experimental design and appropriate controls:

• Sequential immunostaining protocol: For double labeling of KCC-3 with other markers like parvalbumin, follow this validated approach:

  • Apply primary KCC-3 antibody (1:200) for 1.5 hours at room temperature, then overnight at 4°C

  • Wash with 1× PBS (3×10 minutes)

  • Apply secondary FITC-conjugated antibody (1:200) for 2 hours at room temperature

  • Wash and block with unconjugated Fab antibody (1:20) for 1 hour

  • Proceed with second primary antibody (e.g., parvalbumin antibody at 1:750)

  • Apply second secondary antibody with a different fluorophore (e.g., Cy3 at 1:200)

• Confocal microscopy optimization:

  • Use sequential scanning to prevent bleed-through between channels

  • Set appropriate laser power and detector gain to avoid saturation

  • Capture z-stacks to ensure true co-localization in three dimensions

  • Include single-stained controls to set proper imaging parameters

• Quantitative co-localization analysis:

  • Calculate Pearson's or Mander's coefficients to quantify overlap

  • Analyze multiple fields and biological replicates for statistical validity

  • Present co-localization data with appropriate statistical analysis

What are common issues when detecting KCC-3 in Western blots and how can they be resolved?

Several challenges may arise when detecting KCC-3 in Western blots:

• Multiple or unexpected bands: KCC-3 exists in multiple isoforms with different molecular weights. The literature reports bands at approximately 150 kDa (KCC3a), 122 kDa (KCC3b), and 105 kDa (possibly KCC3c) . Additionally, post-translational modifications can alter migration patterns.

  Solution: Include positive control samples with known KCC-3 isoform expression. Compare results using antibodies targeting different epitopes to confirm band identity.

• Weak or absent signal: KCC-3 may be expressed at low levels in some tissues, like cataractous lens tissue where KCC-3 was undetectable despite detection of other KCC isoforms .

  Solution:

  • Increase protein loading (50-100 μg total protein)

  • Optimize antibody concentration and incubation time

  • Consider using enhanced chemiluminescence detection systems

  • Enrich for membrane fractions if studying membrane-localized KCC-3

• High background: Non-specific binding can obscure specific KCC-3 signals.

  Solution:

  • Increase blocking duration (overnight at 4°C)

  • Use 5% BSA instead of milk for blocking and antibody dilution

  • Increase washing duration and detergent concentration

  • Dilute primary antibody further

• Degradation products: Proteolytic degradation during sample preparation can generate artificial bands.

  Solution:

  • Include a comprehensive protease inhibitor cocktail in lysis buffers

  • Process samples at 4°C and avoid freeze-thaw cycles

  • Use freshly prepared samples when possible

How should I interpret contradictory KCC-3 expression data between protein and mRNA levels?

Discrepancies between protein and mRNA levels are common in molecular biology and require careful interpretation:

• Post-transcriptional regulation: KCC-3 may be subject to microRNA regulation or other post-transcriptional mechanisms affecting translation efficiency. Research has shown that factors like IGF-1 and TNF-α can regulate both KCC-3 mRNA and protein levels, suggesting coordinated but potentially distinct regulatory mechanisms .

• Protein stability differences: KCC-3 protein may have different stability/turnover rates compared to its mRNA. Consider performing protein stability assays using cycloheximide chase experiments to determine protein half-life.

• Methodological sensitivity differences: RT-PCR may detect low expression levels that fall below Western blot detection limits. Conversely, accumulated stable protein may be detectable even when mRNA levels are low.

• Tissue-specific post-translational regulation: Research has shown differential expression patterns across tissues. For example, KCC3 mRNA and protein were detected in human lens epithelial B3 cells but only mRNA (not protein) was found in cataractous lens tissue samples .

• Validation approach:

  • Use quantitative RT-PCR rather than standard RT-PCR for precise mRNA quantification

  • Combine with protein quantification via Western blotting

  • Include time-course analyses to capture potential temporal disconnects between mRNA and protein expression

  • Consider polysome profiling to assess translation efficiency

What controls are essential when assessing KCC-3 function in relation to its expression?

Rigorous functional studies of KCC-3 require these essential controls:

• Pharmacological inhibitor controls: Include DIOA, a KCC inhibitor, at appropriate concentrations (e.g., 20 μM) to confirm that observed effects are specifically due to KCC-3 activity. Research has demonstrated that this concentration completely inhibits KCC-3 activity in transfected cells .

• Genetic controls: Compare results between:

  • Wild-type cells/tissues

  • KCC-3 knockout models

  • KCC-3 overexpression systems

  • Inducible KCC-3 expression models (e.g., KCC3-flox x PV-Cre ERT2 models)

• Specificity controls for related transporters: Include controls to rule out contributions from related transporters:

  • Bumetanide (1 μM) to inhibit Na+-K+-2Cl- cotransporter (NKCC)

  • Ouabain to inhibit the Na+-K+ pump

  • These controls help isolate KCC-3-specific effects from those of other ion transporters

• Functional readout validations:

  • For K+ transport studies, use 86Rb+ as a congener of K+

  • Verify Cl- dependence by substituting NO3- or CH3OSO3- for Cl-

  • Include both electrophysiological and flux-based measurements when possible

• Correlation between expression and function: Design experiments that systematically vary KCC-3 expression levels (through induction systems or growth factor/cytokine treatments) and measure corresponding changes in functional outcomes like cell proliferation, ion transport, or regulatory volume decrease .

How can KCC-3 antibodies be utilized in studying neurological disorders associated with KCC-3 dysfunction?

KCC-3 antibodies are valuable tools for investigating neurological disorders:

• Comparative expression analysis: Compare KCC-3 expression patterns between normal and pathological tissues using immunohistochemistry or Western blotting. Research models using accelerated rotarod assays have demonstrated links between KCC-3 expression in parvalbumin-positive neurons and locomotor phenotypes .

• Temporal induction studies: Utilize conditional knockout models (like KCC3-flox x PV-Cre ERT2) to study the temporal requirements of KCC-3 expression. Such models allow for controlled deletion of KCC-3 at specific developmental stages through tamoxifen administration .

• Subcellular localization in disease states: Investigate whether KCC-3 mislocalization contributes to pathology by comparing subcellular distribution patterns between normal and diseased tissues using confocal microscopy with appropriate antibodies.

• Post-translational modification alterations: Use phospho-specific antibodies to determine whether disease states are associated with aberrant KCC-3 phosphorylation patterns, as KCC-3 activity is known to be regulated by tyrosine phosphorylation .

• Therapeutic intervention assessment: Employ KCC-3 antibodies to monitor expression changes following therapeutic interventions aimed at restoring normal KCC-3 function or expression in disease models.

What emerging techniques can enhance KCC-3 antibody-based research?

Several cutting-edge approaches can elevate KCC-3 research:

• Proximity ligation assays (PLA): Detect protein-protein interactions involving KCC-3 with spatial resolution below 40 nm. This technique can reveal interactions between KCC-3 and regulatory proteins or other ion transporters in their native cellular environment.

• Super-resolution microscopy: Techniques like STORM, PALM, or STED microscopy combined with appropriate KCC-3 antibodies can resolve subcellular localization with precision beyond the diffraction limit, potentially revealing organization patterns within membrane microdomains.

• Expansion microscopy: Physical expansion of specimens combined with conventional KCC-3 immunostaining can achieve super-resolution-like results with standard confocal microscopes.

• Live-cell imaging with nanobodies: Single-domain antibody fragments against KCC-3 can enable live-cell imaging of KCC-3 dynamics when conjugated to fluorescent proteins or dyes.

• Mass cytometry (CyTOF): Metal-conjugated KCC-3 antibodies enable high-dimensional analysis of KCC-3 expression alongside dozens of other markers in heterogeneous cell populations.

• Antibody-based proteomics: KCC-3 antibodies can be used for immunoprecipitation followed by mass spectrometry to identify the KCC-3 interactome under various physiological and pathological conditions.